STOCKS TELEGRAPH

Tag: ICCM stock

  • Why IceCure (ICCM) Is Gaining Traction Before The Market Opens?

    Why IceCure (ICCM) Is Gaining Traction Before The Market Opens?

    IceCure Medical Ltd (NASDAQ: ICCM) shares are experiencing a remarkable surge, soaring 105.35% to $1.14 in pre-market trading at last check. On Friday, IceCure stock closed at $0.55 with a modest 0.02% increase. The remarkable upswing follows favorable evaluations of ICCM’s technology in an independent research study.

    What ICCM Technology Was Positively Reviewed?

    IceCure (ICCM) is a trailblazer in medical innovation, celebrated for its development of the ProSense System, a groundbreaking technology that offers a minimally invasive cryoablation approach for tumor removal.

    This innovative approach, presented at the European Society of Breast Imaging (“EUSOBI”) Scientific Meeting in Valencia, Spain, by Dr. Lucía Graña-López, MD, PhD, highlights the potential of cryoablation as an alternative to traditional surgical methods for early-stage breast cancer treatment.

    Dr. Graña-López’s independent study, conducted at the University Hospital Lucus Augusti in Lugo, Spain, focused on 31 patients who declined surgery for various reasons and instead opted for cryoablation using the ProSense System. With a median tumor size of 24 mm, all patients had biopsy-proven early breast cancer.

    The patients were rigorously monitored for up to 40 months, and remarkably, only one patient experienced cancer progression, with no major complications reported in the others.

    This study underscores cryoablation as a viable alternative for breast cancer patients who choose not to undergo surgery, particularly among the elderly population. Dr. Graña-López’s proficient use of ProSense suggests a promising future where cryoablation may replace surgery as the preferred treatment for post-menopausal women with early-stage breast cancer.

    Moreover, ProSense’s potential extends to transforming the treatment landscape for cancers affecting the kidney, lung, and thyroid gland.

    How ProSense Will Help ICCM Excel?

    The global adoption of ProSense by medical practitioners, especially in the context of early-stage breast cancer, demonstrates its efficacy. The dissemination of these findings by dedicated physicians within the medical community is encouraging.

    These findings correspond with the continuous ICE3 investigation conducted by ICCM, the most extensive of its type in the United States, anticipated to be finalized in the initial three months of 2024. This innovative method not only provides optimism to individuals with breast cancer but also possesses the capacity to transform cancer therapy across diverse bodily parts, signifying a substantial progression in the domain of medical knowledge.

  • IceCure Medical Ltd (ICCM) stock has increased by 11.54% in premarket – What’s driving it high?

    IceCure Medical Ltd (ICCM) experienced an increase of 11.54% in premarket following the updates in SEC filing. However, the last trading session closed at $2.59 with an increase of 10.68%.

    Unaudited 2021 Year-End Financial Results – Newest Updates by ICCM

    ICCM announced unaudited 2021 Year-End Financial Results on 31st January 2022. The company reported that revenues increased from $3.9 million to $4.1 million. Moreover, the cash and cash equivalents came out to be $25.6 million. Beginning with a $15 million private placement early in the year 2021 was a critical year for IceCure. Furthermore, ProSense sales have surged in the United States and Europe. This has been possible because of the expansion of our global distribution network. Furthermore, the ICE3 study in the United States produced encouraging results for the cryoablation technology in the treatment of early-stage breast cancer.

    Now what?

    The company plans to enhance its regulatory and commercial strategy in the US, China, and Japan in 2022. In addition, ICCM intends to work with additional commercial strategic partners. Additional regulatory clearances in key markets, such as the United States and China, will be one of the main priorities.

    Furthermore, ICCM has previously submitted a pre-submission package to the Food and Drug Administration in the United States for early-stage breast cancer with a high risk of surgery. Not only this but ICCM has proposed a De Novo categorization based on the ongoing ICE3 clinical study. Lastly, the team is hopeful that the FDA Breakthrough Device Designation will result in a priority review.

    Notice of Intention – Latest Updates by ICCM

    ICCM announced on 20th December 2021, that European Patent Office is willing to issue a patent for IceCure’s “Cryogen Pump” application. IceCure has created a new cryogenic pump that is submersible in liquid nitrogen and operates in a closed circuit. Furthermore, without the requirement to refill liquid nitrogen, this cryogenic pump can be used for repeated procedures or long-term duration procedures. This pump also allows for temperature control of the cryoprobe, as well as the use of a broader range of cryoprobes and catheters and increases the operating temperature during a procedure.